International Conference on Hepatitis Vaccines and Liver Diseases October 24-25, 2016 Valencia, Spain

The best way to prevent hepatitis A is through vaccination with the hepatitis A vaccine. Vaccination is recommended for all children age 12 months and older, for travelers to certain countries, and for people at high risk for infection with the virus.

The hepatitis A vaccine is given as two shots, six months apart. The hepatitis A vaccine also comes in a combination form, containing both hepatitis A and B vaccine, that can be given to persons 18 years of age and older. This form is given as three shots, over a period of six months or as three shots over one month and a booster shot at 12 months.

For Children: The first dose should be given at 12-23 months of age. Children who are not vaccinated by two years of age can be vaccinated at later visits.

For Travelers: Hepatitis A vaccine is recommended for healthy international travelers age 12 months or older; the first dose of Hepatitis A vaccine should be administered as soon as travel is considered. A shot called immune globulin (IG) can be considered in addition to hepatitis A vaccine for older adults, immunocompromised persons, and persons with chronic liver disease or other chronic medical conditions who are traveling within two weeks. IG without hepatitis A vaccine can be given to travelers who are younger than 12 months of age, allergic to a vaccine component, or who elect not to receive vaccine.

For Others: The hepatitis A vaccine series may be started whenever a person is at risk of infection:

• Men who have sexual contact with other men
• Users of certain illegal drugs, both injection and non-injection
• Family and caregivers before arrival of international adoptees
• People with chronic (lifelong) liver diseases.
• People who are treated with clotting-factor concentrates
• People who work with hepatitis A infected animals or in a hepatitis A research laboratory

Hepatitis vaccines 2016 hosting presentations from Global Leaders in the field across the Globe and bringing together vaccine stakeholders including academic researchers, public health clinicians, vaccine policy makers, corporate and vaccine manufacturers. With the generous response and support received from the participants of previous vaccines conferences. OMICS Internationalproudly announces “International Conference on Hepatitis Vaccines” which will be held during June 16–18, 2016 in Rome, Italy. The Theme of the conference is “Innovative research’s & technologies in Hepatitis Vaccines”.

List of Best International Conferences:

• International Conference on Hepatitis Vaccines, July 25-26, 2016, Australia
• 3rd World Congress on Hepatitis and Liver Diseases, Oct 17-19, 2016, UAE
• 2nd International Conference on Hepatology, May 12-14, 2016, USA
• Annual Conference on Virulent HIV Vaccines, July 28-30, 2016, Thailand
• 4th International Conference on HIV/AIDS, STDs, & STIs, Oct 3-5, 2016, USA
• International HBV Meeting, Germany
• HepDart 2015, Hawaii
• The Liver Meeting 2015, USA
• 2nd Hepatitis Cure & Eradication Meeting 2015, Canada
• 4th Canadian Symposium on Hepatitis C Virus, Canada

Hepatitis B is a serious disease caused by a virus that attacks the liver. The virus, which is called hepatitis B virus (HBV), can cause lifelong infection, cirrhosis (scarring) of the liver, liver cancer, liver failure, and death. Hepatitis B vaccine is available for all age groups to prevent HBV infection.

The currently used hepatitis B vaccines are made synthetically (i.e. they do not contain blood products) and have been available in the U.S. since 1986. You cannot get hepatitis B from the vaccine. Learn more.

This safe and effective vaccine is recommended for all infants at birth and for children up to 18 years. Adults, especially those who fall into a high-risk group, should also seriously consider getting the hepatitis B vaccine.

For Children and Adolescents:

All children should get their first dose of hepatitis B vaccine at birth and complete the vaccine series by 6–18 months of age. Hepatitis B vaccine is recommended for all babies so that they will be protected from a serious but preventable disease. Babies and young children are at much greater risk for developing a chronic infection if infected, but the vaccine can prevent this.

All children and adolescents younger than 19 years of age who have not yet gotten the vaccine should also be vaccinated. "Catch-up" vaccination is recommended for children and adolescents who were never vaccinated or who did not get the entire vaccine series.

Hepatitis vaccines 2016 hosting presentations from Global Leaders in the field across the Globe and bringing together vaccine stakeholders including academic researchers, public health clinicians, vaccine policy makers, corporate and vaccine manufacturers. With the generous response and support received from the participants of previous vaccines conferences. OMICS Internationalproudly announces “International Conference on Hepatitis Vaccines” which will be held during June 16–18, 2016 in Rome, Italy. The Theme of the conference is “Innovative research’s & technologies in Hepatitis Vaccines”.

List of Best International Conferences:

• 10th Euro Global Summit and Expo on Vaccines & Vaccination, June 16-18, 2016, Italy
• Annual Conference on H1N1 & Influenza Vaccines, July 25-26, 2016, USA
• International Conference on Hepatitis Vaccines, July 25-26, 2016, Australia
• 11^th Global Summit and Expo on Vaccines & Vaccination, Sept 12-14, 2016, USA
• 13th Asia Pacific Global Summit and Expo on Vaccines & Vaccination, Nov 10-12, 2016, Australia
• The Liver Meeting 2015, USA
• 2nd Hepatitis Cure & Eradication Meeting 2015, Canada
• 4th Canadian Symposium on Hepatitis C Virus, Canada
• The Viral Hepatitis Congress, Germany
• The Singapore Hepatitis Conference, Singapore

Hepatitis C is a contagious liver disease that ranges in severity from a mild illness lasting a few weeks to a serious, lifelong illness that attacks the liver. It results from infection with the Hepatitis C virus (HCV), which is spread primarily through contact with the blood of an infected person. Hepatitis C can be either “acute” or “chronic.”

The virus persists in the liver in about 85% of those infected. This chronic infection can be treated with medication: the standard therapy is a combination of peginterferon and ribavirin, with either boceprevir or telaprevir added in some cases. Overall, 50–80% of people treated are cured. Those who develop cirrhosis or liver cancer may require a liver transplant.

Acute Hepatitis C virus infection is a short-term illness that occurs within the first 6 months after someone is exposed to the Hepatitis C virus. For most people, acute infection leads to chronic infection.

Chronic Hepatitis C virus infection is a long-term illness that occurs when the Hepatitis C virus remains in a person’s body. Hepatitis C virus infection can last a lifetime and lead to serious liver problems, including cirrhosis (scarring of the liver) or liver cancer.

Hepatitis vaccines 2016 hosting presentations from Global Leaders in the field across the Globe and bringing together vaccine stakeholders including academic researchers, public health clinicians, vaccine policy makers, corporate and vaccine manufacturers. With the generous response and support received from the participants of previous vaccines conferences. OMICS Internationalproudly announces “International Conference on Hepatitis Vaccines” which will be held during June 16–18, 2016 in Rome, Italy. The Theme of the conference is “Innovative research’s & technologies in Hepatitis Vaccines”.

List of Best International Conferences:

• International Conference on Hepatitis Vaccines, July 25-26, 2016, Australia
• 3rd World Congress on Hepatitis and Liver Diseases, Oct 17-19, 2016, UAE
• 2nd International Conference on Hepatology, May 12-14, 2016, USA
• Annual Conference on Virulent HIV Vaccines, July 28-30, 2016, Thailand
• 4th International Conference on HIV/AIDS, STDs, & STIs, Oct 3-5, 2016, USA
• International HBV Meeting, Germany
• HepDart 2015, Hawaii
• The Liver Meeting 2015, USA
• 2nd Hepatitis Cure & Eradication Meeting 2015, Canada
• 4th Canadian Symposium on Hepatitis C Virus, Canada

Hepatitis is also classed as a sexually transmitted disease (STD) because it can be passed on sexually, particularly during activities such as anilingus (rimming). The washing of genital and anal areas before sex, and the use of condoms or dental dams can help to prevent this risk. People contract STDs through sexual contact with an infected person. Some STDs have other, nonsexual means of transmission. Risk of contracting STDs can be reduced by avoiding sexual contact or by consistent use of condoms during sexual activity or by practicing safer forms of sexual intimacy. In some cases, people can further reduce their risk for contracting a sexually transmitted disease by being vaccinated.

When symptoms do appear they are similar to those of hepatitis A and may include:

• A short, mild, flu-like illness
• nausea, vomiting and diarrhea
• loss of appetite
• weight loss
• jaundice (yellow skin and whites of eyes, darker yellow urine and pale faeces)
• Itchy skin.

Hepatitis vaccines 2016 hosting presentations from Global Leaders in the field across the Globe and bringing together vaccine stakeholders including academic researchers, public health clinicians, vaccine policy makers, corporate and vaccine manufacturers. With the generous response and support received from the participants of previous vaccines conferences. OMICS Internationalproudly announces “International Conference on Hepatitis Vaccines” which will be held during June 16–18, 2016 in Rome, Italy. The Theme of the conference is “Innovative research’s & technologies in Hepatitis Vaccines”.

List of Best International Conferences:

• 13th Asia Pacific Global Summit and Expo on Vaccines & Vaccination, Nov 10-12, 2016, Australia
• 10th Euro Global Summit and Expo on Vaccines & Vaccination, June 16-18, 2016, Italy
• Annual Conference on H1N1 & Influenza Vaccines, July 25-26, 2016, USA
• International Conference on Hepatitis Vaccines, July 25-26, 2016, Australia
• 11^th Global Summit and Expo on Vaccines & Vaccination, Sept 12-14, 2016, USA
• The Liver Meeting 2015, USA
• 2nd Hepatitis Cure & Eradication Meeting 2015, Canada
• 4th Canadian Symposium on Hepatitis C Virus, Canada
• The Viral Hepatitis Congress, Germany

The Singapore Hepatitis Conference, Singapore

A hepatitis C vaccine, a vaccine capable of protecting against hepatitis C, is not available. Although vaccines exist for hepatitis A and hepatitis B, development of a hepatitis C vaccine has presented challenges. No vaccine is currently available, but several vaccines are currently under development. The ability of the body to make protective antibodies after infection with hepatitis A led researchers to develop vaccines against the disease. Hepatitis A vaccine is made of killed hepatitis A viruses and causes the body's immune system to produce antibodies against the hepatitis A virus.

The first hepatitis B vaccine became commercially available in the United States in 1982. In 1986, a hepatitis B vaccine produced by recombinant DNA technology was licensed and a second recombinant-type hepatitis B vaccine was licensed in 1989. Babies normally get 3 doses of hepatitis B vaccine: 1st Dose: Birth 2nd Dose: 1-2 months of age 3rd Dose: 6-18 months of age Some babies might get 4 doses, for example, if a combination vaccine containing hepatitis B is used.

Hepatitis vaccines 2016 hosting presentations from Global Leaders in the field across the Globe and bringing together vaccine stakeholders including academic researchers, public health clinicians, vaccine policy makers, corporate and vaccine manufacturers. With the generous response and support received from the participants of previous vaccines conferences. OMICS Internationalproudly announces “International Conference on Hepatitis Vaccines” which will be held during June 16–18, 2016 in Rome, Italy. The Theme of the conference is “Innovative research’s & technologies in Hepatitis Vaccines”.

List of Best International Conferences:

• International Conference on Hepatitis Vaccines, July 25-26, 2016, Australia
• 3rd World Congress on Hepatitis and Liver Diseases, Oct 17-19, 2016, UAE
• 2nd International Conference on Hepatology, May 12-14, 2016, USA
• Annual Conference on Virulent HIV Vaccines, July 28-30, 2016, Thailand
• 4th International Conference on HIV/AIDS, STDs, & STIs, Oct 3-5, 2016, USA
• International HBV Meeting, Germany
• HepDart 2015, Hawaii; The Liver Meeting 2015, USA
• 2nd Hepatitis Cure & Eradication Meeting 2015, Canada
• 4th Canadian Symposium on Hepatitis C Virus, Canada

Despite the challenges in studying hepatitis, considerable progress has been in made in characterizing anti-hepatitis immune responses. It has been estimated that approximately 20% of individuals are able to clear the infection spontaneously following acute Hepatitis infection, whereas the rest progresses to chronicity. Longitudinal studies of the two cohorts of patients during and after acute infection have defined immunologic correlates that are associated with viral clearance.

A strong T-cell response, characterized by the production of effector cytokines including IFN-γ, and broad epitope specifically correlate with the resolution of acute infection. After clearance of the acute infection, memory T cells are maintained, but whether they can provide protection against reinfection is incompletely understood. While usually not resulting in sterilizing immunity, that is, prevention of acute infection after re-exposure especially to antigenically more divergent hepatitis strains, adaptive immunity protects against progression to chronic infection following repeated hepatitis exposure. As chronic infection persists, the number of epitopes recognized decreases and T-cell responses are often lost. Since hepatitis-associated morbidity and mortality are caused by chronic infection, a vaccine, even if it only prevents viral persistence, would greatly ameliorate the problem. Although neutralizing antibodies are present during the chronic phase of infection, these antibodies are not able to clear the virus. Several mechanisms of viral escape from antibody-mediated neutralization have been postulated and tested. Recently, several human monoclonal antibodies against hepatitis envelope protein E1 or E2, which show cross neutralizing capability, were identified. These antibodies were able to prevent infection of heterologous hepatitis in the hepatitis pseudo particle and hepatitis cell culture model system, suggesting passive prophylaxis with exogenous neutralizing antibodies or eliciting high-affinity antibodies with similar specificity representing a viable strategy to prevent or more efficiently control hepatitis infections.

Hepatitis vaccines 2016 hosting presentations from Global Leaders in the field across the Globe and bringing together vaccine stakeholders including academic researchers, public health clinicians, vaccine policy makers, corporate and vaccine manufacturers. With the generous response and support received from the participants of previous vaccines conferences. OMICS Internationalproudly announces “International Conference on Hepatitis Vaccines” which will be held during June 16–18, 2016 in Rome, Italy. The Theme of the conference is “Innovative research’s & technologies in Hepatitis Vaccines”.

List of Best International Conferences:

• Annual Conference on H1N1 & Influenza Vaccines, July 25-26, 2016, USA
• 13th Asia Pacific Global Summit and Expo on Vaccines & Vaccination, Nov 10-12, 2016, Australia
• 10th Euro Global Summit and Expo on Vaccines & Vaccination, June 16-18, 2016, Italy
• International Conference on Hepatitis Vaccines, July 25-26, 2016, Australia
• 11^th Global Summit and Expo on Vaccines & Vaccination, Sept 12-14, 2016, USA
• The Liver Meeting 2015, USA
• 2nd Hepatitis Cure & Eradication Meeting 2015, Canada
• 4th Canadian Symposium on Hepatitis C Virus, Canada
• The Viral Hepatitis Congress, Germany
• The Singapore Hepatitis Conference, Singapore

For the purposes of registration, a clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

The first clinical trial of a hepatitis C vaccine in humans has demonstrated safety and unprecedented immune responses, according to research published this week in Science Translational Medicine. B-cells produce antibodies that go after specific invaders. With the hepatitis C virus constantly changing (much like HIV) and having multiple genotypes, it is challenging for scientists to get B-cells to work effectively in a hepatitis C vaccine.

Using “helper” T-cells instead of B-cells that target specific intruders, the new vaccine provokes the immune system to go after the virus with its own defenses. About 15 to 25 percent of people who become infected with hepatitis C clear the virus spontaneously, according to the U.S. Centers for Disease Control and Prevention (CDC). Researchers have known that a powerful T-cell response plays a role in the body’s ability to do so.

The researchers used chimpanzee viruses as vaccine vectors in the trial. “The size and breadth of the immune responses seen in the healthy volunteers are unprecedented in magnitude for a hepatitis C vaccine,” lead researcher Ellie Barnes, of the Nuffield Department of Medicine at Oxford University, said in a press statement.

Hepatitis vaccines 2016 hosting presentations from Global Leaders in the field across the Globe and bringing together vaccine stakeholders including academic researchers, public health clinicians, vaccine policy makers, corporate and vaccine manufacturers. With the generous response and support received from the participants of previous vaccines conferences. OMICS Internationalproudly announces “International Conference on Hepatitis Vaccines” which will be held during June 16–18, 2016 in Rome, Italy. The Theme of the conference is “Innovative research’s & technologies in Hepatitis Vaccines”.

List of Best International Conferences:

• 3rd World Congress on Hepatitis and Liver Diseases, Oct 17-19, 2016, UAE
• 2nd International Conference on Hepatology, May 12-14, 2016, USA
• Annual Conference on Virulent HIV Vaccines, July 28-30, 2016, Thailand
• 4th International Conference on HIV/AIDS, STDs, & STIs, Oct 3-5, 2016, USA
• 2nd Hepatitis Cure & Eradication Meeting 2015, Canada
• 4th Canadian Symposium on Hepatitis C Virus, Canada
• The Viral Hepatitis Congress, Germany
• The Singapore Hepatitis Conference, Singapore

Anyone planning to travel abroad may need immunizations before departure. Although few immunizations are compulsory for international travel, some are recommended for the traveller’s protection. Some vaccines must be given in 2–3 doses several weeks apart. Therefore, a doctor should be consulted at least 2–3 months before departure. Children under 1 year, and people with a compromised immune system or serious underlying disorder may not be able to have some vaccinations, such as those for yellow fever and tuberculosis. Recommended vaccines are travel vaccinations that can protect you in areas where there is an intermediate or high risk for contracting certain illnesses. They also help prevent the spread of diseases from one country to another.

Hepatitis vaccines 2016 hosting presentations from Global Leaders in the field across the Globe and bringing together vaccine stakeholders including academic researchers, public health clinicians, vaccine policy makers, corporate and vaccine manufacturers. With the generous response and support received from the participants of previous vaccines conferences. OMICS Internationalproudly announces “International Conference on Hepatitis Vaccines” which will be held during June 16–18, 2016 in Rome, Italy. The Theme of the conference is “Innovative research’s & technologies in Hepatitis Vaccines”.

List of Best International Conferences:

• Travel Medicine and Vaccines Conference, May 9-11, 2016, SanFrancisco, USA
• 10th Euro Vaccines Conference June 16-18, 2016 Rome, Italy
• 7^th Middle East Vaccines Conference, September 28-30, 2015 Dubai, UAE
• 12th American Vaccines Conference, Oct 20-22, 2016, Dubai, UAE
• 13th Vaccines Asia Pacific Conference, November 10-12, 2016 Melbourne, Australia
• Africa Conference on Infectious Diseases, Emergency Risks and Travel Medicine, Nigeria
• Infectious Diseases in the Adult Patient: A Primary Care Update, USA
• The 15th Conference of the International Society of Travel Medicine, Spain,
•  Asia Pacific Travel Health Conference , Nepal
• The 1st Croatian Congress on Travel, Tropical, Migration Medicine & HIV with international participation, Croatia.

That investigation forecasts the overall hepatitis therapies market will multiply in revenues from 2014 to 2025. That pharmaceutical segment is evolving. Newly approved medications are achieving commercial success and some products blockbuster status. Visiongain believes the strength of the hepatitis drugs market is its oral antiviral treatments enabling shorter treatment regimens and higher cure rates, reportedly with fewer side effects than the standard care – peginterferon and ribavirin. Sales expansion of the market will be stimulated by the approval and continued development of interferon- and ribavirin-free regimens as well as increased screening. The potential for the hepatitis therapies market is vast and budgetary cuts and regulatory hurdles will not derail its progress.

 “In 2014, the greatest interest in the hepatitis C market is the development of protease and polymerase antivirals. Several companies have molecules in phase II and III trials, with at least five expected to gain approval within the first half of our forecast period. The overall world hepatitis C drug market was worth $4bn in 2013, and we expect it to multiply in annual revenue by 2025. There exists promising R&D for those medicines, with high sales potential from this decade onwards. That market is rapidly developing and will contribute high revenues to the pharmaceuticals industry from 2015 to 2025.”

Hepatitis vaccines 2016 hosting presentations from Global Leaders in the field across the Globe and bringing together vaccine stakeholders including academic researchers, public health clinicians, vaccine policy makers, corporate and vaccine manufacturers. With the generous response and support received from the participants of previous vaccines conferences. OMICS Internationalproudly announces “International Conference on Hepatitis Vaccines” which will be held during June 16–18, 2016 in Rome, Italy. The Theme of the conference is “Innovative research’s & technologies in Hepatitis Vaccines”.

List of Best International Conferences:

• International Conference on Hepatitis Vaccines, July 25-26, 2016, Australia
• 3rd World Congress on Hepatitis and Liver Diseases, Oct 17-19, 2016, UAE
• 2nd International Conference on Hepatology, May 12-14, 2016, USA
• Annual Conference on Virulent HIV Vaccines, July 28-30, 2016, Thailand
• 4th International Conference on HIV/AIDS, STDs, & STIs, Oct 3-5, 2016, USA
• International HBV Meeting, Germany
• HepDart 2015, Hawaii; The Liver Meeting 2015, USA
• 2nd Hepatitis Cure & Eradication Meeting 2015, Canada
• 4th Canadian Symposium on Hepatitis C Virus, Canada

Epidemiology is the science that studies the patterns, causes, and effects of health and disease conditions in defined populations. It is the cornerstone of public health, and shapes policy decisions and evidence-based practice by identifying risk factors for disease and targets for preventive healthcare.

Hepatitis B virus (HBV) infection is a global public health problem. It is estimated that there are 240 million HBV carriers in the world, of whom roughly 600,000 die annually from HBV-related liver disease. The implementation of effective vaccination programs in many countries has resulted in a significant decrease in the incidence of acute hepatitis B. Nevertheless, hepatitis B remains an important cause of morbidity and mortality.

The spectrum of clinical manifestations of HBV infection varies in both acute and chronic disease. During the acute phase, manifestations range from subclinical or anicteric hepatitis to icteric hepatitis and, in some cases, fulminant hepatitis. During the chronic phase, manifestations range from an asymptomatic carrier state to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Extra hepatic manifestations also can occur with both acute and chronic infection.

Hepatitis vaccines 2016 hosting presentations from Global Leaders in the field across the Globe and bringing together vaccine stakeholders including academic researchers, public health clinicians, vaccine policy makers, corporate and vaccine manufacturers. With the generous response and support received from the participants of previous vaccines conferences. OMICS Internationalproudly announces “International Conference on Hepatitis Vaccines” which will be held during June 16–18, 2016 in Rome, Italy. The Theme of the conference is “Innovative research’s & technologies in Hepatitis Vaccines”.

List of Best International Conferences:

• 12th Global Vaccines & Vaccination Summit and Expo, Oct 20-22, 2016, UAE
• 10th Euro Global Summit and Expo on Vaccines & Vaccination, June 16-18, 2016, Italy
• Annual Conference on H1N1 & Influenza Vaccines, July 25-26, 2016, USA
• 11^th Global Summit and Expo on Vaccines & Vaccination, Sept 12-14, 2016, USA
• 13th Asia Pacific Global Summit and Expo on Vaccines & Vaccination, Nov 10-12, 2016, Australia
• Epidemiology and Prevention of Vaccine Preventable Diseases Conference, USA
• European Scientific Conference on Applied Infectious Disease Epidemiology, Sweden
• Epidemiology and Prevention of Vaccine-Preventable Diseases, USA
• World Vaccine Congress, USA
• Global Conference on Vaccines, UAE